|Last Updated: October 1, 2022 @ 9:13 am|
PSA, Ultrasensitive Total and Free
|Stability:||Ambient: 8 Hour(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable|
|Interpretive Data:||Please see report for interpretive data.|
The Roche e801 PSA electrochemiluminescent immunoassay is the test methodology used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche e801 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche e801 PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
Probability of finding prostate cancer on needle biopsy by age in years
Age in Years
% fPSA ratio 50-59 60-69 >69
<11 49.2 % 57.5 % 64.5 %
11-18 26.9 % 33.9 % 40.8 %
19-25 18.3 % 23.9 % 29.7 %
> 25 9.1 % 12.2 % 15.8 %
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may interfere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.